Free tool
NTAP cost threshold check
Pick the MS-DRG your device's cases group to, enter your estimated average charges per case including the device, and see whether you likely clear the CMS cost threshold for FY 2028 NTAP applications.
Quick answer
The NTAP cost threshold is the average charge per case, set by CMS for each MS-DRG every fiscal year, that a new technology must exceed to qualify for a New Technology Add-on Payment. This free tool checks your estimated charges against the official CMS thresholds for FY 2028 NTAP applications.
The cost criterion is one of three NTAP tests; CMS also reviews newness and substantial clinical improvement. Informational only, not reimbursement advice.
FY 2028 NTAP timeline
- Application deadline: Applications for FY 2028 NTAP are typically due in early-to-mid October 2026.
- IPPS Proposed Rule: CMS publishes its proposed NTAP decisions for public comment.
- FDA marketing authorization: Technology must receive FDA authorization by May 1 (July 1 for breakthrough devices).
- IPPS Final Rule: CMS finalizes NTAP approvals and posts the next cycle's thresholds.
- Payments begin: NTAP payments start with FY 2028 discharges.
NTAP questions
- What is the NTAP cost threshold?
- It is the minimum average charge per case, set by CMS for each MS-DRG every fiscal year, that a new technology's cases must exceed to meet the NTAP cost criterion. CMS publishes the thresholds in the IPPS final rule tables.
- How is NTAP calculated?
- If CMS approves NTAP, Medicare generally pays 65% of the amount by which a case's costs exceed the standard MS-DRG payment, capped at 65% of the technology's cost (75% for certain qualifying antimicrobial products), under 42 CFR 412.88.
- When are NTAP applications due?
- Applications are typically due in October for the next fiscal year. CMS discusses applicants in the IPPS proposed rule in spring and decides in the final rule around August, with payments starting October 1.
- Does meeting the cost threshold guarantee NTAP?
- No. The cost criterion is one of three tests. CMS also requires that the technology is new and that it offers a substantial clinical improvement, unless it qualifies for an alternative pathway such as Breakthrough Device designation.
Need the full picture?
MedTech Compass adds five years of Medicare DRG discharge volumes, CMS payment weights, the estimated NTAP add-on payment per case and a branded PDF for your team.
Open the full analysis in MedTech CompassPrimary sources
Go beyond lookup
Describe your device in plain language and get AI-assisted triage: likely classification, product codes, premarket pathway, EU MDR and UK considerations — with evidence citations and global market scoring.
Data shown on this page comes from the U.S. Food and Drug Administration's public openFDA APIs and is provided for research convenience. MedTechCompass is not affiliated with the FDA. Verify all regulatory details against the official FDA databases before relying on them.